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Oral squamous cell carcinoma is the most prevalent of all malignancies arising 
from the oral cavity and could result in severe morbidities and mortality if not 
promptly identified and treated. It accounted for 30% of all head and neck 
cancers [90]. The rich lymphatic drainage in this region makes these tumors to 
show a high incidence of metastasis to regional cervical lymph nodes [30]. 
Cancers arising in the oral cavity have been demonstrated to have a high 
metastatic rate of well over 50% [140]. Neck node status is the single most 
important prognostic factor in oral cancers and other head and neck cancers 
[26]. The incidence of lymph node metastases of these cancers depends 
largely on histo-pathologic factors like tumor thickness, perineural and 
microvascular invasions, lymphocytic inflammatory infiltration, pattern of tumor 
invasion and differentiation, and molecular tumor markers [45,58,140,150]. 
Tumor size greater than 2cm and tumor invasion depth of more than 4mm are 
known risk factors for nodal metastasis [97,135]. The degree of histologic 
differentiation and tumor staging also play a significant role in nodal 
metastases. The incidence of nodal metastases is higher in poorly 
differentiated and late stage diseases [140]. However, in the American Joint 
Committee on Cancer (AJCC) 2010 classification system, pT1-2N0 oral cavity 
squamous cell carcinomas are considered to be the early stage cancer [41]. 
The staging system is similar to that of the International Union Against Cancer 
(IUCC) 2009 [141]. 
 
A subset of oral cancer patients without clinical evidence of regional 
metastases is known to harbor occult metastases. Unfortunately, there is still 
no examination method that can validly detect micro-metastasis in 
cervical lymph nodes during evaluation of these patients. Available imaging 
methods such as computed tomography (CT) scan, magnetic resonance 
imaging (MRI), positron emission tomography (PET) and ultrasound-guided fine 
needle aspiration biopsy have been shown to have significant false-negative 
and false-positive rates [35]. Also, there has not been accurate biomarker that 
can reliably identify or predict the presence of occult cervical metastases. 
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Therefore, histologic examination of the neck specimen is the single most 
important and reliable investigation to detect neck nodal metastasis.  
 
The great challenges in the management of these patients by surgeons and 
radiotherapists include the identification of the patients with true clinically node-
negative neck (N0 neck) and determination of the extent of appropriate therapy 
that will not be regarded as over treatment. Optimal treatment for carcinomas of 
the oral cavity with clinical N0 neck remained a controversial issue. Primary 
tumor control can be achieved by an appropriate surgical operation with or 
without radiotherapy. However, controversies exist on the management of the 
neck in clinically node-negative neck (N0) patients although; the available 
management policies include observation, elective neck dissection, or 
irradiation [71,99,169]. Even though there is no universal consensus guideline 
on the management of the neck in squamous cell carcinoma of oral cavity with 
clinical N0 necks, the predominant opinion is elective neck dissection 
[117,136]. Elective neck dissection refers to dissection of cervical lymphatics 
and fibrofatty tissues in the absence of an obvious clinical or radiological 
evidence of neck node metastasis for either staging or therapeutic purposes. 
Those who advocate for neck treatment stated that most of those patients 
whose necks are observed eventually develop nodal metastasis and are 
usually detected at an advanced stage of the disease with poor management 
outcome. The benefits of neck dissection as advocated by this group include 
successful reduction of regional recurrence, pathological staging of neck, 
avoidance of unnecessary neck irradiation and indication of cases where 
adjunct therapy should be employed [45,58,71,97,99,140,150,169]. 
Nevertheless, there is still an unresolved controversy on its benefits in the 
eventual regional control and survival compared with the policy of observation 
[46,157]. The advocators of observation or ‘watchful waiting’ policy after the 
removal of the primary tumor have stated that elective neck dissection in 
clinically N0 necks is just a diagnostic staging procedure rather than a 
therapeutic operation hence unjustifiable [66]. They recommended close 
watching of the neck during follow-up of these patients and performance of 
therapeutic neck dissection only if cervical metastases developed [116]. 
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Nevertheless, the primary oral lesion in the patients which qualify for this 
observation policy must have fulfilled the criteria for low risk lymphatic 
metastases which include small size primary tumor (less than 2cm), minimal 
depth invasion (e.g. less than 4mm in primary tumor of the tongue), and 
favorable histologic differentiation [41,135]. They proposed a reliance on the 
radiological evaluation of the neck to take decision on the extent of treatment 
[55] and emphasized on the importance of frozen section as a guide on 
whether or not to proceed to neck dissection [122]. 
 
1.1 The relevant anatomy of the oral cavity  
The oral cavity is bounded anteriorly by the vermilion border of the upper and 
lower lips and posteriorly by the circumvallate papillae of the tongue, the 
junction of the hard and soft palates, and the anterior faucial arch. However, 
the subsites in the oral cavity include [6,158]:   
· Lips: The oral cavity portion of the lip includes only the vermilion surface 
or portion of the lip that comes in contact with the opposing lip. The 
lower lip primarily drains to the submental and submandibular nodes but 
there could be bilateral metastasis because of the anastomoses of the 
lymphatic vessels with the opposite side. However, the upper lip drains 
primarily to the preauricular, periparotid and submandibular nodes. 
· Buccal mucosa: This includes the mucosa of upper and lower lips, cheek 
mucosa, upper and lower bucco-alveolar sulci (vestibule of mouth) and 
retromolar trigone. The lymphatics from buccal mucosa drain to the 
periparotid, submental and submandibular nodes. 
· Upper and lower alveolar ridges and gingiva: Also known as upper and 
lower gums. The lymphatic drainage of the buccal aspect is to the 
submental and submandibular nodes while that of the lingual aspect is to 
the upper deep jugular and retropharyngeal nodes. 
· Hard palate: extends from the inner surface of the superior alveolar ridge 
to the posterior edge of the palatine bone. The lymphatic drainage is into 
the jugular and retropharyngeal nodes. 
· Oral tongue: is the anterior 2/3rd of the tongue which is mobile and 
extends from the tip to the circumvallate and the junction at the floor of 
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the mouth. It has four anatomical areas: tip, lateral borders, and dorsal 
and ventral surfaces. The anterior portion of oral tongue drains into the 
submental nodes while the lateral portion drains into the submandibular 
and upper jugular nodes. There is a rich lymphatic network with bilateral 
communication across the midline; therefore drainage also enters 
contralateral neck nodes.  
· Floor of mouth: is a semilunar space extending from the lower alveolus 
to anterior tonsillar pillars posteriorly. It has both superficial and deep 
lymphatic drainage system. The superficial system crosses randomly in 
the midline and drains into the submandibular nodes bilaterally. The 
deep system drains into the ipsilateral submandibular and upper jugular 
nodes. 
· Retromolar trigone: is a triangular shaped area overlying the ascending 
ramus of the mandible from the last molar (base of the triangle) to the 
apex which terminates in the maxillary tuberosity superiorly. The 


















Figure 1: Diagrammatic illustration of anatomy of the Oral cavity and its 
subsites (Pictures adapted from Beth Israel Medical Center, St. Luke’s and 










1.2     Lymphatic drainage of the oral cavity 
The oral cavity has an extensive lymphatic drainage system. Several important 
lymph node groups act as first-echelon nodes for the oral cavity. In the 
submental triangle, two or three nodes lie on the omohyoid muscle. The 
submandibular triangle contains six or more nodes which lie on the surface of 
the submandibular gland. Included within this triangle are the facial nodes, pre- 
and postvascular, which are related to facial artery. Alveolar ridge, lip, and oral 
vestibule commonly drain to the submental and submandibular nodes (level I) 
[6,158,162,163]. 
 
More inferiorly, the superior deep jugular nodes are major target of drainage 
from the oral cavity (Level II). They are located along the superior aspect of the 
internal jugular vein between the levels of the digastric and omohyoid muscles. 
Less common nodal groups receiving the primary lymphatic from oral cavity 
include the lateral retropharyngeal nodes and the nodes adjacent to the inferior 
portion of the parotid gland (periparotid nodes). Cancer of the hard palate with 
extension into the maxillary sinus and buccal cancers can drain into the 
retropharyngeal and periparotid nodes respectively. As multiple cervical nodes 
become involved with metastasis, spread to the middle jugular nodes (level III) 
occurs [6,88,158,162,163]. 
 
The study by Rouviere has shown that the lymphatic drainage of the mucosal 
surfaces of the head and neck occur relatively constant and to predictable 
routes, not in haphazard fashion [127]. Lindberg [92] in 1972 demonstrated that 
the lymph node groups most frequently involved in patients with cancers of the 
oral cavity are the superior cervical lymph nodes. Furthermore, these cancers 
frequently metastasize to both sides of the neck. However, in the absence of 
metastasis to the first echelon lymph nodes, tumors of the oral cavity rarely 
involve the inferior cervical lymph node groups. Shaha et al [134] found 
metastasis in nodes of the posterior triangle of the neck in only 5% of patients 
with cancers of the oral cavity. These studies have led to the now popular 
practice of removing only the submental, submandibular, superior and middle 
jugular lymph nodes (Level I, II and III) in patients having cancer of the oral 
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cavity with clinically node-negative neck (N0 Neck). This procedure is known as 
the supraomohyoid neck dissection and has been shown to be a valid staging 
procedure in these patients [16,79,162] and is an example of how knowledge of 
the lymphatic anatomy of the oral cavity has led to effective management of 
lymphatic metastasis. 
 
1.3 Statements of the problem 
1) Which patients with clinical N0 neck actually have no cancer cells in the 
cervical lymphatics? 
2) Which patients with clinical N0 neck will eventually develop neck node 
metastasis? 
3) Which treatment modality is most optimal and least morbid for the 
treatment of clinical N0 neck in oral carcinomas? 
4) Does elective neck dissection in N0 neck disease confer significant 
outcome benefits compared to the policy of observation or watchful 
waiting? 
 
1.4 Justification of the study 
There is no greater controversy on the management of head and neck cancers 
than the optimal treatment for clinical N0 necks. Researchers have 
demonstrated that clinical N0 necks have shown occult metastases in about 
30% or higher, depending on the size, site of primary tumor and the histological 
diagnostic methods [21,118]. The great challenge that is being faced by the 
head and neck oncologists and surgeons is the correct identification of the 
subset of head and neck cancer patients, of which oral carcinoma constitutes 
about 30% [90], without micro metastases to the cervical lymph nodes. Clinical 
palpation of the neck combined with the radiological investigative tools has not 
been able to correctly identify all these patients [39,102,130]. Despite the 
increase in knowledge and advancement in cancer management, there is still 
no method to determine correctly the real micro metastatic disease free neck. 
Although squamous cell carcinoma of the oral cavity is a locally aggressive 
disease with a great tendency for loco-regional and distant metastasis, 
researchers have shown that not all the cancers will metastasize, especially at 
14 
 
the early stage. Treating the neck which is actually node-negative means 
incurring unnecessary costs, prolong hospital stay and causing avoidable 
morbidity. However, when the neck is not included in the management plan for 
the primary tumor in a clinically N0 neck but with actually unrecognized micro 
metastases, the implication of this is poor treatment outcome with increased 
morbidity and mortality rate.  
 
The morbidity from the disease usually results from the impairment of the 
inherent physiologic functions that usually take place in the head and neck 
region. This may include problems with breathing, swallowing, phonation, 
speech, olfaction and taste. However, the advancement in management 
strategies of oral squamous cell carcinoma, which includes significant loco-
regional disease control, surgical reconstruction to restore these functions and 
rehabilitation, has significantly reduced these loco-regional morbidities. The 
quality of life of these oral cancer patients has also improved as compared to 
the past, even in those who eventually succumbed to distant metastasis or the 
disease progression. Despite the advances in cancer therapies, it is only 
possible to achieve an increase survival outcome or cure in patients with early 
disease if appropriate and optimal therapy is offered. The patients presenting 
with late stage diseases are usually left to faith and palliative therapies are 
usually offered.  
 
The reality is that some patients with a clinical N0 neck indeed have no cancer 
cells in their cervical lymphatics and their neck must not be over treated. In 
employing proper oncologic therapy for the neck, one must balance the desire 
to preserve the present function of the neck with the wish to prevent future 
morbidity or loss of neck function. This requires that all persons involved in the 
multimodality treatment of oral carcinomas; surgeons, radiation oncologists, 
and medical oncologists be open to trying a unique therapeutic approach that 
may achieve the desired goal, while minimizing morbidity. Although there are 
many available retrospective studies on oral cancer patients with clinical N0 
necks and modalities of therapies but there is no consensus on the unique 
therapeutic approach. Few prospective studies are available but there is still 
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inconclusive evidence on whether elective neck dissection is of any value over 
observation/ therapeutic neck dissection in oral cancers with N0 neck. Most of 
these studies have study designs which are opened to bias and their sample 
sizes are small. Therefore, a systematic review of prospective randomized 
controlled trials is needed to answer these questions owing to the inherently 
biased nature of available studies. Only few of such randomized controlled 
trials are available in the literature and none of these studies have a study 
population above eighty patients. Therefore a critical assessment and 
interpretation of the literatures which combine and compare the results of these 
studies with a meta-analysis is necessary for a better evidence to support 
either of these two modalities of treatment. This study therefore systematically 
reviewed the existing published literatures on the unresolved questions of the 
benefits of elective neck dissection in oral cancers with N0 neck. Meta-analysis 
was then performed on published data of randomized control trials on elective 
versus observation/ therapeutic neck dissection.  
 
1.5 Research question 
Does elective neck dissection provide therapeutic benefit to patients with oral 
squamous cell carcinomas with clinical N0 neck? 
 
1.6 Hypothesis 
Elective neck dissection does not provide therapeutic benefit to patients with 













2 Study objectives 
The scientific aim of this study is to assess the benefits of elective neck 
dissection in oral squamous cell carcinomas with clinically node-negative neck. 
All the available published randomized controlled trials on the subject matter 
were pooled together in a meta-analysis: 
1. To evaluate the effectiveness of elective neck dissection in the 
successful reduction of neck node recurrence in oral squamous cell 
carcinoma with clinical N0 neck 
2. To determine and compare the disease specific death rate of elective 
neck dissection to policy of observation in oral squamous cell carcinoma 
with clinical N0 neck. 
3. To compare the survival outcome of elective neck dissection to the 























3 Materials and method 
3.1 Type of study 
This was a comprehensive systematic review of all relevant studies which 
compared elective neck dissection to the policy of observation/ therapeutic 
neck dissection in oral squamous cell carcinoma with clinical N0 neck. The 
staging of oral squamous cell carcinoma was as described by the American 
Joint Committee on Cancer 2010 classification system [41] which was similar to 
that of the International Union Against Cancer (IUCC) 2009 [141]. In the meta-
analysis, the PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses) guideline [101] for randomized trials was followed. 
 
3.2 Study Design 
It was a meta-analysis of all prospective randomized controlled trials on 
elective neck dissection versus observation/ therapeutic neck dissection for 
clinical N0 neck in oral cancers. 
 
3.3 Type of participants 
All age groups with the diagnosis of oral squamous cell carcinoma with N0 
neck disease. 
 
3.4 Topography, nomenclature and physiology of the lymphatic system 
of the neck 
The head and neck region has a rich network of lymphatic vessels draining 
from the base of skull through the jugular nodes, the spinal accessory nodes 
and the transverse cervical nodes down to the venous jugulo-subclavian 
confluent or the thoracic duct on the left side and the lymphatic duct on the right 
side [65,158]. Embryologically, the lymphatic vascular system develops from 
buds of venous endothelium that unite to form vessels [158]. These lymphatic 
vessels are lined by contractile endothelial cells which contain actin-like 
filaments. The physiologic function of the lymphatic system is to return 
interstitial fluids, plasma, and cells to the blood stream. Continuous contraction 
of the lymph vessels, the pumping action of adjacent blood vessels, and 
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compression of the interstitial tissue by the surrounding muscles allow passage 
of lymph in the interstitium through clefts and into the lymphatic capillaries [13].  
 
In the classic model, lymph flows from the capillaries through afferent vessels 
and into the marginal sinus in the cortex of the first echelon lymph node. The 
marginal sinus then drains into the hilar efferent channels directly or into 
smaller channels that penetrate and form a complex anastomotic network in the 
medulla of the lymph node. From the hilar efferent channels, lymph flows into 
the lymphatic trunks, joining lymph from neighboring groups of nodes. The 
valved lymphatic trunks then drain into three terminal collecting ducts: the 
thoracic, subclavian, and right lymphatic ducts. Lymph is then returned to the 
venous system at the junctions of the internal jugular and subclavian veins. 
Sometimes, lymph flow may completely bypass any intercurrent lymph node via 
pericapsular channels that have been demonstrated to connect the afferent and 
efferent lymphatics [171]. Processes like metastatic tumor cell infiltration and 
reactive lymph node hyperplasia that increase the hydrostatic pressure in the 
intervening lymph node have been shown to increase the flow through the path 
of least resistance at the pericapsular channels [119,146].  
 
Rouviere is credited with the classic anatomic description of the lymphatic 
drainage of the head and neck based on anatomic landmarks found on 
palpation [127]. Although his description is exhaustive and produced an 
influential classification but it has been further modified by others to suit the 
need of clinicians [53,54,94,142]. Clinically, the roughly 300 lymph nodes, 150 
per side, are now generally broken down into groups or levels. The 
understanding of this system of lymph node levels has helped clinicians to 
determine the specific area of neck metastasis especially in aerodigestive 
cancers and in decision making on selective neck dissection. This has been 
classified as follows: lymph nodes at the submental and submandibular (level 
I), upper jugular (level II), middle jugular (level III), lower jugular (level IV), 
posterior triangle which contain spinal accessory and transverse cervical nerve 
(level V), and anterior compartment (level VI). However, there are still some 
clinically important lymph node groups at the head and neck region which are 
19 
 
not included in any of the classic lymph node levels. These include the facial 
nodes (mandibular, buccinator, infraorbital, malar, and retrozygomatic), the 
retropharyngeal nodes of Rouviere, the tracheoesophageal and paratracheal 
nodes, the periparotid and intraparotid nodes, the postauricular node, the 
superficial occipital node, and the upper mediastinal lymph nodes [151]. 
 






3.4.1 Level I Lymph Nodes 
Level I includes the lymphatic contents of the submental space (Sublevel Ia) 
and submandibular (Sublevel Ib) space [142]. The submandibular space is 
bound anteriorly by the anterior belly of the digastric muscle, posteriorly by the 
posterior belly of the digastric muscle, laterally by the mandible, and superiorly 
by the mylohyoid and hyoglossus muscles. Rouviere [127] originally described 
five groups of submandibular lymph nodes (preglandular, retroglandular, 
prevascular, retrovascular, and intracapsular submandibular lymph nodes). To 










node) even though its presence is inconsistent. The preglandular group, usually 
consisting of one to two nodes, is usually located anterior to the submandibular 
gland and lateral to the anterior belly of the digastric muscle and embedded in 
fibrofatty tissue. The retroglandular node, usually singular and inconsistent, is 
found medial to the mandible immediately posterior to the submandibular 
gland. The prevascular node, usually singular, lies anterior to the anterior facial 
vein and superficial to the facial artery. The retrovascular nodes, usually one to 
two in number, are somewhat more variable in location, but are frequently 
found in the angle between the anterior and posterior facial veins. The 
intracapsular or intraglandular nodes are located within the parenchyma of the 
submandibular gland. The inconsistent “deep” submandibular node is located 
deep to the submandibular gland but superficial to the mylohyoid or hyoglossus 
muscles. The submental lymph nodes receive their efferent lymphatics from the 
skin of the chin, the mid lower lip, the tip of the tongue, and much of the 
mucosa of the anterior floor of mouth. The submandibular nodes receive 
efferent lymphatics not only from the submental lymph node but also from the 
medial canthal areas, lower nasal cavity, palliative vault, soft palate, maxillary 
and mandibular alveolar ridges, cheeks, upper and lower lips, lateral chin, and 
most of the anterior tongue. The superficial oral collecting lymphatic capillaries 
form a mucosal network with significant anastomotic crossover, which drains 
into a submucosal or muscular network of trunks which, in turn, drain into the 
submental, submandibular, and carotid triangles [17]. In addition, animal 
studies have demonstrated the presence of mandibular periostial lymphatics 
with subsequent drainage to the submandibular or upper deep cervical nodes 
[108].  
 
3.4.2 Level II Lymph Nodes 
Level II contains the upper jugular lymph nodes located around the upper one 
third of the internal jugular vein and adjacent spinal accessory nerve. It is 
bound anteriorly by the lateral border of the sternohyoid muscle, posteriorly by 
the posterior border of the sternocleidomastoid muscle, and superiorly by the 
skull base. The inferior border is defined surgically by the carotid bifurcation 
and clinically and radiographically by the hyoid bone. The number of nodes 
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varies from one to five but the highest node lie in contact with the posterior 
belly of the digastrics muscle and this is referred to as the jugulodigastric node 
or principle node of Kuttner [127]. Level II lymph nodes have been further 
subclassified into sublevel IIa and IIb [54,163]. The border of the stylohyoid 
muscle was used to separate sublevel Ib from sublevel IIa. This has been 
found not to be a practical marker during clinical examination and on 
radiological imaging. The vertical plane which is defined by the posterior edge 
of the submandibular gland has now been recommended [126]. Lymph nodes 
that lie anterior (media) to this plane are defined as occupying level I, whereas 
those lying posterior (or lateral) to it are defined as occupying level II. In case of 
nodes which transgress this plane, the determination will be based on whether 
more than half of the node volume is located medial or lateral to the plane 
[126,163]. Sublevel IIa contains nodes in the region anterior to the spinal 
accessory nerve while Sublevel IIb contains nodes in the region posterior to the 
spinal accessory nerve. The level II group receives efferent lymphatics from the 
facial, pre- and postauricular parotid, and submandibular, submental, and 
retropharyngeal nodal groups. Level II also directly receives the collecting 
lymphatics from the nasal cavity, pharynx, larynx, external auditory canal, 
middle ear, tongue, hard and soft palate, faucial tonsils, and sublingual and 
submandibular glands [127]. 
 
3.4.3 Level III Lymph Nodes 
Level III contains the middle jugular lymph nodes located around the middle 
one third of the internal jugular vein. It is bound anteriorly by the lateral border 
of the sternohyoid muscle, posteriorly by the posterior border of the 
sternocleidomastoid muscle, and superiorly by the inferior border of level II 
(carotid bifurcation or hyoid bone). The inferior border is defined surgically by 
the junction of the omohyoid muscle and the internal jugular vein, and clinically 
by cricothyroid notch and radiologically by the cricoid cartilage. Level III 
contains a highly variable number of nodes, with a dominant supraomohyoid 
node, and receives efferent lymphatics from level II and level V, some efferent 
lymphatics from the retropharyngeal, pretracheal, and recurrent laryngeal 
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nodes and collecting lymphatics from the tongue base, tonsil, larynx, 
hypopharynx, and thyroid gland [127]. 
 
3.4.4 Level IV lymph nodes 
This contains the lower jugular lymph node located around the lower one third 
of the internal jugular vein. It is bound anteriorly by the posterior border of the 
sternohyoid muscle, posteriorly by the posterior border of the 
sternocleidomastoid muscle, superiorly by the inferior border of level III 
(cricothyroid notch or junction of omohyoid and Internal jugular vein or cricoid 
cartilage), and inferiorly by the clavicle. Level IV also contains a variable 
number of nodes and receives efferent lymphatics primarily from level III and 
level V, some efferent lymphatics from the retropharyngeal, pretracheal, and 
recurrent laryngeal nodes and collecting lymphatics from the hypopharynx, 
larynx, and thyroid gland [127]. 
 
3.4.5 Level V Lymph Nodes 
Level V contains all the lymph nodes in the posterior triangle of the neck. It is 
bound anteriorly by the posterior border of the sternocleidomastoid muscle, 
posteriorly by the anterior border of the trapezius muscle, superiorly by the 
mastoid process and inferiorly by the clavicle. Level V contains five to 10 nodes 
and receives efferent lymphatics from the occipital and postauricular nodes as 
well as collectively lymphatics from the occipital and parietal scalp, the skin of 
the lateral and posterior neck and shoulder, tonsils, tongue base, and 
nasopharynx [127,164]. 
 
3.4.6 Level VI Lymph Nodes 
Level VI, also called the anterior central compartment lymph node group, 
contains the lymph nodes in the visceral space. It is bound laterally by the 
medial borders of the carotid sheaths, superiorly by the hyoid bone, and 
inferiorly by the suprasternal notch. Level VI receives efferent lymphatics from 
the thyroid gland, larynx, hypopharynx, and cervical esophagus [127,163]. This 
level has been described and separated from level III and IV by the lateral 
border of sternocleidomastoid muscle. Because this landmark cannot be easily 
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identified on radiological imaging, medial aspect of common carotid artery has 
been recommended [126].  
 
3.5 Staging of oral squamous cell carcinoma [41,112,141] 
Tumor 
§ T1 - 2 cm or less 
§ T2 - > 2 cm but ≤ 4 cm 
§ T3 - >4 cm 
§ T4 (Lip) - Invades through cortical bone, inferior alveolar nerve, floor of 
mouth, or skin of face (i.e. chin or nose) 
§ T4a (Oral cavity) - Invades through cortical bone, deep (extrinsic) 
muscle of tongue, maxillary sinus, or skin of face 
§ T4b - Involves masticator space, pterygoid plates, or skull base, or 
encases internal carotid artery 
 
Node 
§ NX - Cannot be assessed 
§ N0 - No regional lymph nodes metastasis 
§ N1 - Single ipsilateral lymph node, <  3cm in greatest dimension 
§ N2 – Lymph node between 3 and 6cm in its greatest diameter 
- N2a - Single ipsilateral lymph node, 3-6 cm in greatest 
dimension 
- N2b - Multiple ipsilateral lymph nodes, not more than 6cm 
in greatest dimension 
- N2c - Bilateral or contralateral lymph nodes, not more than 
6cm in greatest dimension 
§ N3 - Lymph node(s) >6 cm in greatest dimension 
 
Metastasis 
§ M0 - none 






§ I - T1 N0 
§ II - T2 N0 
§ III - T3 N0, T1-3 N1 
§ IVA - T4a, N2 
§ IVB - T4b, N3 
§ IVC - M1 
 
Note : T: Tumor; N: Node; M: Metastasis 
 
3.6 Diagnosing the node-negative neck 
Node-negative neck disease conventionally refers to clinically non-palpable 
neck nodes but this is a grossly inadequate and inaccurate method of 
identifying metastatic neck node [4,21,114,121,133]. Researchers have 
demonstrated that clinical N0 necks have shown occult metastases in about 
30% or higher, depending on the size, site of primary tumor and the histological 
diagnostic methods [21,118]. Some large nodes may be inflammatory while 
some impalpable nodes may be carcinomatous [32,108]. Clinical palpation of 
the neck is not adequate for the correct identification of patients with neck node 
metastasis [39,102,130]. Factors such as neck fat thickness, neck stiffness or 
contraction, pain and swelling may affect the identification of neck node by 
palpation. However, the combination of neck palpation and radiologic 
evaluation of the neck with computerized tomographic (CT) scan and/or 
magnetic resonance imaging, and ultrasound and ultrasound-guided fine 
needle biopsy for cytology of the suspected node have been shown to provide 
an improved accuracy of detecting metastatic neck node or diseases 
[27,145,156]. Ultrasound guided fine needle aspiration cytology is reliable to 
some extent at identifying lymph node metastases in carcinoma of the oral 
cavity and other head and neck cancers which were previously impossible. In 
recent publications related to the detection of cervical metastases, sensitivity 
rates of ultrasonography, magnetic resonance imaging (MRI), computed 
tomography (CT), the 18F-fluorodeoxyglucose (FDG)-positron emission 
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tomography (PET) and PET/CT are in the range of about 70 – 80% 
[3,61,83,167,168]. 
 
These radiological investigative tools are valuable in assessing those nodes in 
the head and neck sites that are not easily and readily accessible to palpation, 
such as the retropharyngeal, paratracheal, and upper mediastinal nodes, and in 
assessing extranodal disease. The malignancy criteria on CT scan and MRI 
include minimal diameter of 15 mm for nodes located in level II and 10 mm for 
nodes located in other levels; spherical shape, groups of three or more 
borderline nodes (1 to 2 mm smaller); nodes of any size with evidence of 
central necrosis; and soft tissue invasion or loss of tissue planes (fat planes) 
[27,39,68,102,154]. However, these radiological investigative tools are not 
without limitations. Small areas of necrosis are not always depicted clearly and 
adipose metaplasia or area of hypovascularity could mimic necrosis on CT 
scan [39]. An estimated 50% of cervical metastases are less than 5.0 mm [39]. 
Studies have also shown that 46 – 67% cases of malignant lymph node 
matastases will be missed by CT scan, confirmed by histologic evaluation of 
whole neck specimens [39,56]. In a study, the sensitivity of CT staging is 
estimated to be 25%, and the specificity 77% [130]. Therefore, pathologic 
staging is the most accurate tool available to assess the status of the cervical 
lymphatics. 
 
Extracapsular extension of nodal metastasis, on the other hand, can be most 
reliably detected only on pathologic examination of the node in question 
because current radiologic imaging techniques are not adequately accurate. 
However, as individual predictors of metastasis, the histologic data have not 
been consistently and strongly correlated. Histopathologic factors like tumor 
thickness, perineural and microvascular invasions, lymphocytic inflammatory 
infiltration, pattern of tumor invasion and differentiation, and molecular tumor 
markers have been advocated to be reliable metastastic potential parameters 
[45,58,97,150,166]. A report on a multivariable clinicopathologic scoring system 
in which points were allotted to each individual variable or predictor has been 
document [135]. The points were then summed up to yield a multivariable 
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metastatic potential, based on characteristics of the primary tumor. Though 
limited to the oral cavity and oropharynx, this innovation in histologic 
examination may prove valuable in assessing the risk of cervical metastasis.  
 
Another innovation, which has emerged from the advances in molecular 
genetics, is molecular staging of head and neck cancer patients [155]. 
Molecular staging uses the polymerase chain reaction to amplify and assay the 
tumor suppressor gene p53 (from the surgical specimen). The molecular 
probing is highly sensitive and is reported to have the capacity to detect one 
cancer cell among 10,000 normal cells. Although only available at a few 
centers, preliminary data showed that these techniques improve the ability to 
predict loco-regional recurrence [18]. 
 
Histologic features of the primary tumor have been combined with molecular 
genetics to predict cervical lymph node metastasis. This study combined 
histologic features of the primary tumor with immunohistochemical studies of 
cell adhesion molecules, tumor suppressor genes and DNA analysis of 
oncogenic amplification. Their correlation has been used to predict the 
possibility of cervical metastasis in patients with laryngeal carcinoma [150]. 
This type of study may actually revolutionize the way oral cancers and other 
head and neck cancers are staged in the future.  
 
In the treatment of oral squamous cell carcinomas, control of the primary tumor 
is very important to the survival outcome of the affected patient. Hence, the 
single most important therapeutic intervention for oral squamous cell carcinoma 
is the complete surgical removal of the primary tumor. This may sometimes not 
be achievable, especially in late stage diseases due to the extent of the tumor 
and its relation to the vital adjacent structures. Failure to achieve a complete 
surgical primary tumor removal will lead to poor treatment outcome and even, 
early death [82]. Cervical lymph node metastasis increases the risk of loco-
regional recurrence and distant metastatic spread and correlates with a 50% 




3.7 The Criteria for inclusion in the study include: 
- The studies must be randomized controlled trials  
- The patients in the studies must have no clinical and radiological 
evidences of neck node metastasis (N0 neck) 
- The study must have compared elective neck dissection (END) with 
observation / therapeutic neck dissection (OBS)  in patients with oral 
cavity cancers  
 
3.8 Exclusion criteria included studies which did not meet the above 
mentioned criteria or in which the randomization was missing. 
 
3.9      Search strategy and method for identification of study  
A comprehensive search of articles published in English in the following 
electronic databases: MEDLINE (1966 – 2010), EMBASE (1988 – 2010), 
Cochrane Central Register of Controlled Trials, Scopus and Google scholar 
was carried out. Despite this restriction to articles published in English 
language, there was no identification of studies published in other languages. 
To retrieve publications reporting on randomized controlled trials on elective 
neck dissection versus observation/ therapeutic neck dissection in oral cavity 
cancers, a combined search strategy that included the following terms as both 
medical subject heading (MeSH) terms and text words was performed. The key 
terms used to search the electronic database included “randomized controlled 
trial”, “oral cavity cancers”, “elective neck dissection”, “therapeutic neck 
dissection”, “observation” and “N0 neck”. All, and then some of these terms 
were used in combination for the search. Some books and reference list of 
each article obtained were checked for further potential studies (Figure 3). The 
authors of one of the original articles [169] included in the study were contacted 
for additional information.  
 
3.10 Validity method of assessment 
The identified studies were assessed based on the intended objectives for the 
study. Only the trials which met the criteria were included in the meta-analysis. 
Data from the studies were then extracted and collated. 
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3.11 Type of intervention  
All the studies randomized the patients into two groups {[Elective neck 
dissection (END) and Observation or Therapeutic neck dissection (OBS) 
group}.  
END group had primary neck dissection at the time of the treatment of 
the primary tumor. 
OBS group had treatment of the primary tumor only but the neck was put 
under closed observation during follow up. Neck dissection was 
performed only when neck node metastasis was detected and this was 
therapeutic neck dissection.  
 
3.12 The development of surgical procedures for the treatment of 
cervical lymph node metastases 
In the 19th century, lymphatic metastasis in patients with head and neck cancer 
was considered by many surgeons as a sign of an incurable disease [49]. The 
removal of individual lymph node metastases with the resection of the primary 
tumor presented a less effective therapeutic outcome in the patients at that 
time. In 1880, Kocher reported on the detailed description of the surgical 
technique for the removal of lymph nodes from submandibular triangle during 
the surgical treatment of tongue cancer [80]. In 1882, Volkmann reported on 
lymph node dissection along with resection of the internal jugular vein [160]. A 
short period later, the concept of prophylactic or elective removal of neck lymph 
nodes was developed. In 1885, Butlin recommended in his publication that 
during surgical excision of carcinoma of the tongue, elective removal of the 
neck lymph nodes must be performed [20]. In 1888, a polish surgeon called 
Franciszek Jawdynski described an en-bloc resection of lymph node 
metastases, which was later in 1906 popularised and described by Crile as 
radical neck dissection [32]. The morbidity and complications associated with 
radical neck dissection (RND) is high [49]. In order to reduce this morbidity 
associated with RND, a modification of the classic RND was developed at the 
beginning of 20th century by surgeons so as to maintain function and at the 
same time not compromising oncologic treatment outcome [9,96]. Nahum 
described a syndrome of decreased range of abduction in the shoulder joint 
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and pain following RND which has been termed 'shoulder syndrome' [104]. The 
cause of this syndrome is damage to or removal of the spinal accessory nerve 
(SAN) during neck dissection. The preservation of this structure during neck 
dissection was found to ameliorate this syndrome [137]. The realization that it 
was possible to perform a complete en-block lymphadenectomy with 
preservation of structures such as the spinal accessory nerve led to the 
development of the less morbid procedures and the original concept of which is 
credited to Bocca [12]. The classical modified radical neck dissection (MRND) 
involved the removal of cervical lymph nodes from levels I to V and retaining 
some or all the non-lymphatic structures. The ability to harvest neck nodes in 
an operation that limits morbidity has led to a more proactive approach to the 
treatment of cervical disease. In the 80’s of last century, the concept of 
selective neck dissection (SND) was developed. This concept erupted out of 
the understanding that carcinomas from certain region or site of the head and 
neck metastasize only to specified neck levels [92]. Many clinicians now 
advocate selective neck dissections in those patients whose primary site 
characteristics would suggest a high rate of occult metastasis. 
 
3.13 Classification of neck dissection 
Neck dissection is a surgical procedure for the control of neck lymph node 
metastasis from the primary tumor. The aim is to remove all lymph nodes from 
one or both sides of the neck into which cancer cells might have migrated or 
suspected to have migrated. Various modifications of neck dissection have 
been described till date. However, American Head and Neck Society (AHNS) 
and the American Academy of Otolaryngology-Head and Neck Surgery (AAO-
HNS) have proposed a classification into radical neck dissection, modified 
radical neck dissection, selective neck dissection and extended neck dissection 
[124]. Radical neck dissection (RND) involves the removal of all ipsilateral 
cervical lymph node groups from levels I through to V, together with SAN, 
sternocleidomastoid muscle (SCM) and internal jugular vein (IJV). Modified 
radical neck dissection (MRND) involves the removal of all lymph node groups 
routinely removed in a RND, but with preservation of one or more non-
lymphatic structures (SAN, SCM and IJV). Selective neck dissection is 
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cervical lymphadenectomy with preservation of one or more lymph node groups 
that are routinely removed in a RND. Its description involves the use of 
parentheses to denote or represent the specific levels or sublevels of neck 
contents removed. No non-lymphatic structures that are routinely removed by 
RND are removed. An increasing body of evidence suggests that ‘‘less can 
sometimes mean more’’ [50]. Prospective randomized studies which compared 
the efficacy of SND with that of MRND in patients with clinically node-negative 
neck have demonstrated the therapeutic equivalence of the two different 
surgical options [15,16]. Thus for oral cavity cancers, SND (I-III) is commonly 
performed. Extended neck dissection refers to the removal of one or more 
additional lymph node groups or non-lymphatic structures, or both, not 
encompassed by the RND [113]. 
 
3.14 Data extraction 
The extracted data included study design and characteristics (Table 1), sample 
size and study group distribution (Table 2), pathologic distribution of the groups 
and follow up periods (Table 3), neck recurrences and metastasis (Table 4), 
disease-specific deaths in each group, survival and death outcome (Table 5). 
 
3.15 Outcome measures  
The primary endpoint variable for this meta-analysis was disease-specific death 
in the groups. Outcome data on overall deaths, survival, neck nodal 
recurrences and metastasis in each group were also obtained. 
 
3.16 Statistical analyses  
The analysis was performed using the R program for statistical computing (R 
2.10.1; “meta” package). The relative risk (RR) of disease-specific death and 
95% confidence interval (CI) were calculated for each individual study. 
Between-study heterogeneity was not found to be significant as indicated by an 
I2 of 8.5% (p=0.350), however, due to the small number of studies included, 
both fixed-effects (Mantel-Haenszel method) and random-effects models 
(DerSimonian and Laird [36] method) were applied to obtain a combined RR 
estimate, 95% CI and p-value. The inverse variance method of weighting 
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studies (results not shown) was also used, but the results of our meta-analysis 
did not differ between these methods with regard to combined RR estimates 


































In the systematic review, four randomized controlled trials with a total of 283 
patients were identified and these were eligible for inclusion into the meta-
analyses (Table 1, Figure 3) [46,79,157,169]. Three of these were single-center 
studies which took place in France [157], India [46], and Brazil [79] 
respectively. The most recently completed study from Yuen et al was 
performed as a multi-center trial in Hong Kong [169]. These trials took place 
over four decades with the first patients recruited in 1966 [157] and the last in 
2004 [169]. The descriptive statistics of the studies are as shown in Table 2. All 
the studies randomized their patients into END group and OBS group and the 
main study objective of each study was to determine the benefit of elective 
neck dissection for clinical N0 neck in oral cancers. There was no statistical 
difference between these two groups in terms of sex and age of patients, 
histologic type and tumor staging. All the trials reported on pathologic 
distributions (Table 3), neck recurrences and metastasis (Table 4), survival and 
death outcome (Table 5). There were few missed data but the studies have a 
very low rate of interventional crossovers. However, the follow up duration 
varied between the studies but the least follow up period was 12months due to 
death (Table 3). The treatment modality of the primary tumor in three studies 
was surgery while the study by Vandenbrouck et al had treatment of the 
primary tumor with interstitial curietherapy with iridium-192 [157]. All the trials 
had neck dissection in addition to the treatment of the primary tumor in END 
group. For the primary outcome of survival benefits, all the trials with the 
exception of the study by Kligerman et al reported no survival benefit of elective 
neck dissection over observation. However, all of these trials individually 
showed lower disease-specific death rates in the END group compared with the 
OBS group, but only in the study by Kligerman et al [79] was significance 
reached (Figure 4). However, the meta-analyses of these studies showed that 
elective neck dissection may reduce the risk of death from the disease thereby, 
increasing the chance of survival (Figure 5), {fixed-effects model RR=0.57, 95% 
CI of 0.36 - 0.89, p=0.014; random-effects model RR=0.59, 95% CI of 0.37 - 























613 records identified through 
database searching 8 additional records identified through 
the reference lists of articles obtained 
Total of 621 potentially relevant articles 
identified 
16 full text articles identified and assessed for 
eligibility 
605 articles excluded based 
on title and abstracts 
4 studies included in the meta-
analysis 
10 full text articles excluded 
because they were 
retrospective studies 
1 full text article excluded 
because it was a preliminary 
report of one of the included 
studies 
1 full text article excluded 
because it compared effect of 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































OBS = Observation/ Therapeutic neck dissection group 





Figure 5: Forest plot showing relative risk (RR) of disease-specific mortality and 95% 
confidence interval (CI) in each of the studies and the combined estimates 
Figure 4: Forest plot showing relative risk (RR) of the disease-specific death and 




An in-depth review of all the randomized controlled trials included in this meta-
analysis showed that there were a few variations in the trials such as race, 
period of study, and duration of follow-up. Although the data used in this meta-
analysis were from different parts of the world, the heterogeneity of the trials 
were tested and there was no statistical significant difference [I2=8.5%, 
p=0.3504] (Figure 5). In all the randomized controlled trials included in this 
meta-analysis, there were more male patients with oral cavity cancers than 
female. This may be because more males were exposed to the predisposing 
factors especially cigarette/tobacco and alcohol than the females. However, a 
close inspection of all the studies showed that, in the most recent study by 
Yuen et al [167], there was a significant reduction in the gender ratio difference. 
This may be because of the change in the social life-style of women in most 
part of the developed and developing countries which is now similar to that of 
men [138].  
 
The majority of oral cavity cancers are of squamous cell origin and the site 
most commonly affected by this tumor in the oral cavity is the anterior two 
thirds of the tongue and followed by the floor of the mouth [6]. Other subsites of 
the oral cavity are infrequently involved [6]. This may explain the reason why all 
the studies in this meta-analysis reported on the cancer of the anterior two third 
of the tongue (Table 1). However, Kligerman et al and Vandenbrouck et al 
reported on additional few cases of cancers of the floor of the mouth in their 
series [79,157]. 
  
Over 6,000 new cases of oral cavity carcinomas are diagnosed every year. It 
accounted for 4 – 5% of all malignancies in men and 2% of all malignancies in 
women [74,138], and accounted for 3% of all cancer deaths in men and 1% of 
all cancer deaths in women [138]. The morbidity from the disease usually 
results from the impairment of the inherent physiologic functions that usually 
take place in the head and neck region. This may include problems with 
breathing, swallowing, phonation, speech, olfaction and taste. However, the 
advancement in management strategies of oral squamous cell carcinoma, 
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which includes significant loco-regional disease control, surgical reconstruction 
to restore these functions and rehabilitation, has significantly reduced these 
loco-regional morbidities. There has been a decline in the death rate till date 
due to the improved methods of diagnosis and treatment of oral cancers 
[73].The quality of life of these oral cancer patients has also improved as 
compared to the past, even in those who eventually succumbed to distant 
metastasis or the disease progression. Despite the advances in cancer 
therapies, it is only possible to achieve an improved survival time or cure rate in 
patients with early disease or N0 neck if appropriate, optimal and adequate 
therapy is offered. However, the patients presenting with a late stage diseases 
are usually offered palliative therapies.  
 
Only four randomized controlled trials were included in this meta-analysis 
[46,79,157,169]. The fact that only four studies have been successfully 
performed and published is a testament to the difficulties associated with well 
designed prospective randomized controlled trials in oral cavity cancers. Some 
of the problems associated with this kind of trials may include obtaining 
informed consent, uninfluenced allocation or randomization of patients into 
study groups, masking of investigators, study personnel and patients from the 
allocated intervention, adherence to the study protocol, and tracking or follow-
up of patients and outcomes. Despite this small number, the evidence that 
favors elective neck dissection seems to be robust after the pooling effect of 
meta-analysis. The treatment modality of the primary tumor in all the studies 
was by surgical therapy except the study by Vandenbrouck et al where 
radiation therapy was used [46,79,157,169]. However, Ord et al have reported 
that the five-year survival rates in early stage (I and II) oral squamous cell 
carcinoma treated with either surgery or radiotherapy are similar [107].  
 
For the primary outcome of this meta-analysis, disease-specific death rate was 
chosen as the most clinically meaningful endpoint to measure the benefit of 
elective neck dissection. Although homogeneity in the relative risk between 
studies was statistically indicated (p=0.350), one still observed heterogeneity in 
the estimated disease-specific death rates within each treatment group. In the 
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OBS group, these range from 11% to 42 % and in the END group, from 12% to 
30% (Table 2). This observed difference within each group might be due to the 
availability of more sophisticated investigative tools for the early identification of 
neck node metastasis with better sensitivity and specificity in recent times 
[3,16,83,167,168]. Some of the occult metastasis could now be better detected 
during evaluation and properly staged. For example, what would have been 
wrongly staged as N0 in the past when these investigative tools were not 
available can now be better and correctly staged as N1 or N2 as the case may 
be during neck evaluation before primary therapy. This is evident in the most 
recent study by Yuen et al that showed a reduction in the incidence of disease-
specific death rate when compared to the other older studies within the OBS 
group (Table 2). In more than 60% of oral tongue carcinoma patients, disease-
related death is due to uncontrolled neck disease [6]. However, the percentage 
of these deaths which can be attributed to the policy of watchful waiting or 
observation in patients with clinically N0 neck is still unclear. It is also still very 
difficult to separately identify the actual deaths due specifically to neck 
pathology (nodal recurrences or metastases) from oral cancers.   
 
The benefits of elective neck dissection in patients with oral cavity tumors with 
clinical N0 neck are still not clear because the results of numerous existing 
studies on the topic have been generally inconclusive. Most studies have failed 
to show statistically significant differences in survival outcome between the 
patients with oral cavity cancers with clinically N0 neck in END and OBS 
groups [40,46,157,169]. However, there have been few studies which showed 
a significant survival benefit in favor of elective neck dissection in oral 
carcinoma patients with clinically N0 neck [36,62,76,94,170]. Among 
prospective randomized trials, only the study by Kligerman et al showed 
evidence of a statistically significant disease-free survival benefit of elective 
neck dissection over a policy of observation [79] (Table 5 and Figure 4). 
However, this meta-analysis showed that being in the END group significantly 
reduced the risk of death due to the disease. It is possible that this observed 
pooled effect in the meta-analysis between END and OBS might have been 
largely influenced by the older studies. Perhaps, if similar studies are 
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conducted now that there are better investigative tools to detect and better 
stage neck node metastasis, this observed difference may be absent. 
 
In all the four studies, it was observed that the elective neck dissection 
markedly improved the regional control because fewer patients in the END 
group developed neck nodal recurrences or metastasis than those in the OBS 
group. In the END group, nodal recurrence was detected in 6% – 30% of the 
patients while in the OBS group, nodal metastasis was detected in 37% – 58% 
of the patients (Table 4). This may not really be a surprise as the patients in 
END group already had removal of the lymphatic and fibro fatty tissues in their 
neck. Hence, the use of neck node recurrence in the END group or metastasis 
in the OBS group as an outcome measure to advocate for neck dissection in 
oral cancers with clinical N0 neck is not justifiable. This already existing bias is 
the reason why in this meta-analysis, neck node recurrence or metastasis was 
not considered as a primary outcome measure.  
 
The patients whose necks were observed tended to have more regional 
recurrences [40,138] and the results of the salvage treatment of the neck were 
generally poor [37,40,46,76,81]. Nodal metastasis has been considered a 
significant prognostic factor in oral cavity cancers and other head and neck 
malignancies [6,13,118,135]. Even when the tumor is small and considered to 
be an early stage, it is potentially aggressive and the incidence of neck node 
metastases is very high. Patients with T1N0 and T2N0 squamous cell 
carcinoma of the oral cavity have been reported to have occult metastases in 
13-33% and 37-53% respectively at the time of diagnosis [7,21,62,118,152]. 
This is similar to the findings from all the randomized controlled trials in this 
meta-analysis (Table 4). Only Vandenbrouck et al included T3N0 patients in 
their study and this may actually explain the reason why they reported a higher 
rate of extra capsular nodal spread in their study than in other trials. Presence 





The depth or thickness of the primary tumor has been shown to be an 
important factor in neck metastasis, if the tumor depth exceeds 4mm, the risk of 
developing occult metastasis in the neck is increased to between 38 – 70% 
[8,84,105]. Tumor thickness is therefore an important pathologic factor to 
identify the patients at greater risk of developing neck node metastasis. 
Unfortunately, only Kligerman et al and Fakih et al in this meta-analysis 
considered checking for tumor thickness or depth hence, could not be 
examined for its impact on disease-specific death rate due to incomplete data 
[46,79]. However, their individual studies confirmed and showed a strong 
association of tumor thickness with loco-regional recurrences and survival. 
Fakih et al reported 92% occult metastases in patients with tumor thickness 
more than 4mm who had elective neck dissection as against 33% in patients 
with tumor thickness less than 4mm [46]. This value was a little bit higher than 
what other studies have reported [8,84,105]. The same study also showed a 
survival rate of 81% in patients with tumor depth of less than 4mm as 
compared to 43% for those with tumor depth greater than 4mm [46]. The 
thickness or depth of primary tumor is therefore an important determining index 
on whether or not to perform elective neck dissection in oral squamous cell 
carcinomas.  
 
The lymphatic drainage of the oral cavity is commonly to the levels I, II and III 
[6,26,66,162]. Byers et al have reported finding “skip metastases” to lymph 
nodes in levels III and/or IV in 15.8% of the patients with cancer of the oral 
tongue and therefore recommended inclusion of the lymph nodes of level IV 
whenever an elective neck dissection is to be performed in any patient with 
cancer of the oral tongue [22]. However, Khafif et al reported that occult 
metastasis to lymph nodes in level IV from T1-T3N0 oral tongue cancer is very 
rare with an incidence of 4% and therefore, suggested extension of elective 
neck dissection to lymph nodes in level IV only when the intraoperative findings 
of metastases in levels II and III indicate an increased risk of tumor recurrence 
in the neck [77]. Shaha et al reported metastasis in nodes of the posterior 
triangle of the neck in 5% of patients with cancer of the oral cavity [134]. When 
the cancer is in the midline, bilateral neck metastasis can occur [6,45]. 
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Metastases of the tongue carcinoma to the lingual lymph nodes have been 
documented [109].  
 
All the studies except that by Kligerman et al reported no statistical survival 
benefit of elective neck dissection hence, did not recommend routine elective 
neck dissection for patients with clinically N0 neck. They however suggested 
concurrent neck treatment with the surgical extirpation of the primary tumor if 
the tumor depth is more than 4mm or if the patient cannot be regularly 
followed-up. However, a few retrospective studies have reported on the survival 
benefit of elective neck dissection in oral carcinoma with clinical N0 neck 
[37,62,76,94]. It has also been reported that the survival rate of patients with 
oral carcinomas will reduce by 50% once there is a palpable cervical lymph 
node [42,52,87,132]. In this meta-analysis, it was found out that elective neck 
dissection in oral carcinoma with N0 neck can significantly reduce disease-
specific death rate and neck node recurrences. However, there was no 
significant survival benefit of elective neck dissection over the policy of wait-
and-watch/ observation/therapeutic neck dissection.  
 
Carcinogenesis is a fundamental disorder of cellular growth control arising from 
prolonged exposure to physical or chemical mutagens. The accumulation of 
serial mutations in a cell’s genes disrupts the normal growth and differentiation 
and gives the mutated cells a growth advantage over the surrounding host 
cells. Numerous chemicals have been implicated as mutagens in 
carcinogenesis. However, in the mechanism of cancer metastasis, a great deal 
of interplay exists among the putative chemical carcinogens, oncogenic viruses 
and tumor suppressor genes.  
 
Tobacco and alcohol are important risk factors for the development of oral 
cancers. These carcinogens act synergistically and may increase the likelihood 
of developing cancer by up to 30-folds [35,67,85,144,159]. Other environmental 
risk factors include irradiation, wood dust, nickel, chromium, chewing of 
tobacco, areca and betel nut, petrochemicals. Pre-malignant lesions like 
leukoplakia and erythroplakia have also been implicated. 
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Viruses such as human papilloma virus (HPV), Epstein-Barr virus (EBV) and 
Human immunodeficiency virus (HIV) have also been implicated in 
carcinogenesis. The exact role of these viruses has not been fully elucidated, 
but some compelling associations have shown that they cause the activation of 
a proto-oncogene that induces cancer growth. HPV types 16 and 18 have been 
found to contribute to the in vivo malignant transformation of the keratinocyte 
[64,93,103]. HPV DNA is known to be closely associated with poorly 
differentiated cancers, positive lymph nodes and late-stage disease, which all 
indicate poor prognosis. Contradictory to this, patients with HPV positive 
squamous cell carcinomas of the oral cavity and other head and neck regions 
seem to have significantly improved response to chemotherapy and 
radiotherapy as compared with HPV-negative tumors [23,24,149]. The 
association of HPV and the development of inverted papilloma and recurrent 
respiratory papillomatosis and, the risk of transformation to carcinoma of the 
sinonasal region and larynx respectively have been well documented 
[10,75,86]. The strong association between undifferentiated nasopharyngeal 
carcinoma and EBV is well known [47,59]. Tobacco and alcohol are not risk 
factors for undifferentiated nasopharyngeal carcinoma, and there is no 
increased risk of second head and neck primary tumors from this site [31]. 
Immunosuppressed persons are at greater risk of developing malignancies. In 
human immunodeficiency virus (HIV) immunosuppression the most common 
oral cancers are Kaposi's sarcoma and non-Hodgkin's lymphoma. Squamous 
cell carcinoma has also been reported to be associated with HIV infection 
[29,44,120]. 
 
Advances in molecular biology have revolutionized the ability to investigate the 
specific genetic mutations responsible for the evolution of malignant cells. 
Specific genetic elements that suppress cancer growth called tumor suppressor 
genes have been described. The p53 gene, located on chromosome 17p, is 
one of the most intensely studied tumor suppressor genes and its abnormality 
has been reportedly associated with the development of head and neck 
squamous cell carcinoma [14,51,93,114,129]. Its mechanism of action differs 
from the viral-induced carcinogenesis model in that it is the loss of one or both 
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alleles of a tumor suppressor gene that induces cancer growth rather than the 
activation of proto-oncogenes.  
 
The HPV types 16 and 18 produce two proteins, E6 and E7, which directly 
increase the proliferative life span of keratinocytes [64,103] and indirectly 
encourage the proliferation by binding the proteins of tumor suppressor genes 
p53 and RB-1 [70]. E6 and E7 are also involved in the degradation of p53 
[33,164]. As previously mentioned, smoking is associated with an increase in 
the likelihood of developing head and neck squamous cell carcinoma. 
Molecular genetic studies have shown that the frequency of fragile sites on 
chromosome llq13 is significantly higher in peripheral blood lymphocytes of 
smokers than those of nonsmokers [11,100,165]. Chromosome llq13 
amplification is found in one third to one half of head and neck tumor 
specimens and associated with a high histologic grade in those specimens 
[11,165]. The amplification of llq13 is associated with a poor prognosis in 
patients with head and neck squamous cell carcinoma [100].  
 
After the primary tumor has established itself in the mucosa, the first step in the 
mechanism of cancer metastasis is breach of the basement membrane 
[153,171]. The basement membrane is composed primarily of type IV collagen, 
which forms the structural scaffolding of the basement membrane, laminin, and 
proteoglycans. The destruction of these components of the basement 
membrane by hydrolases elaborated by the tumor allows the local, regional, 
and distant movement of the tumor cells [13]. These hydrolases include 
urokinase- type plasminogen activator, several collagenases, and stromalysins. 
Urokinase-type plasminogen activator activates plasmin, which degrades 
laminin. Plasmin also controls the production of type IV collagenase, which 
degrades type IV collagen. Type I collagenase degrades type I collagen 
(fibrillar collagen), which makes up most of the extracellular matrix [13]. The 
amplification of segments of chromosome llq13 can result to changes in the 
tumor cell cytoskeleton which, in turn, can lead to an increase in the cell's 
metastatic potential [28].  
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The mode of cancer spread is in three main ways. The first is direct extension 
from the primary site to adjacent areas. The second is spread through the 
lymphatic channels to lymph nodes. The third is spread through the blood 
vessels to distant sites in the body. In oral cavity cancers and other head and 
neck cancers, a spread to the lymph nodes in the neck is relatively common. 
 
Before gaining access to the circulation, tumor cells or groups of tumor cells 
must dislodge from the primary tumor and survive in neck lymph nodes. This is 
the beginning of metastatic neck node. The filter and barrier function of the 
lymph node appears to be effective at the initial stage, as lymphatic spread is 
generally limited initially to the first echelon of lymph nodes [26,65]. As a lymph 
node is progressively replaced by metastatic tumor, the local lymphatic flow 
may be distorted, reflected and perhaps reversed, directing new lymph borne 
tumor cells to fresh nodes. The cancerous node itself may act as a focus for 
further tertiary spread [28,153]. The blood circulation (blood more so than 
lymph) is a hostile environment for cancer cells, and most cells released into 
the circulation die before they successfully exit the circulation [28]. Finally, once 
the tumor cells have successfully exited the circulation, they must invade the 
new tissue and survive in the new location. There is interplay among 
mechanical factors and other host-tumor interactions which control secondary 
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The extent of treatment of oral cavity cancers depends on the extent of the 
primary tumor, presence of locoregional spread or distant metastases and 
presence of intercurrent medical disease. These factors also contribute to the 
survival outcome of such patients. The treatment modalities for oral carcinomas 
may include surgery, radiotherapy, chemotherapy, combination of any of these 
modalities and biologic therapy (only in few centers) [106,110]. The latest 
National Comprehensive Cancer Network (NCCN) practical guideline 
recommended that most oral cancers be treated by concurrent chemo 
radiotherapy (CCRT), rather than by surgery with or without adjunct therapy. In 
fact, surgery is being viewed as the equivalent of definite radiotherapy (RT) for 
only T1-2, N0-1 cancers. This guideline implies that the treatment outcomes of 
RT and CCRT are better than or equivalent to that of surgery with or without 
adjunct RT, which is the traditional treatment protocol. The 3-year disease free 
survival rate using primary radiation therapy is about 85% for T1N0 oral 
carcinoma and 64% for T2N0 oral carcinoma, similar to surgical treatment [88]. 
In the randomised controlled trials in this meta-analysis, the disease free 
survival rates are as shown in Table 5. Vandenbrouck et al however reported a 
value of 46% when interstitial iridium was used to treat the primary oral tumors 
[157]. This supported the findings by Wang that cone electron beam boost 
technique provides a superior cure rate when compared to interstitial implant 
for early stage oral carcinoma [161]. However, one of the problems of using 
radiotherapy as curative treatment for oral cavity tumor is the proximity of the 
mandibular arch. Notwithstanding, the choice of modality of treatment of the 
primary oral carcinoma depends on the protocol of treatment in different 
centers. However, when the primary tumor is being treated with surgery, 
elective neck dissection may be carried out and when radiotherapy is being 
used to treat the primary tumor, elective irradiation of the neck is performed 
[47]. However, the five-year survival rates are similar in early stage oral 
squamous cell carcinoma treated with either surgery or radiotherapy [107].  
 
Oral squamous cell carcinoma results from the accumulation of genetic and 
tissue damage in a field exposed to a carcinogen. This process can be 
interrupted or reversed through the use of natural or synthetic agents, defined 
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as chemoprevention [111]. However, in established cases of oral carcinomas or 
other head and neck cancers, chemotherapy has been demonstrated to play a 
significant role in their management [43,115,128,148]. Chemotherapy is the 
use of anti-cancer (cytotoxic) drugs to destroy cancer cells. They work by 
disrupting the growth of cancer cells. Chemotherapeutic agents have a role in 
the palliative treatment of oral squamous cell carcinomas or in people whose 
cancers have spread to other parts of their body or whose cancers have come 
back after radiotherapy or surgical therapy.  
 
The use of chemotherapy alone has been shown not to have any evidence of 
increased survival [57] hence, not recommended. In general, chemotherapy for 
oral squamous cell cancer has been used in three settings: as neoadjuvant or 
induction chemotherapy before locoregional treatment with surgery or radiation, 
as adjuvant post-op chemotherapy usually with radiation or as concurrent 
chemoradiotherapy for advanced disease with an intention of down staging the 
tumor [1,2,5,9]. Currently used agents include cisplatin, carboplatin, 5-
fluorouracil and the taxanes (paclitaxel and docetaxel). The 5-fluorouracil and 
taxanes are also regarded as radiation sensitizers [125]. Recent interest has 
been shown in intra-arterial delivery of chemotherapy, which increases the drug 
dose to the tumor and decreases systemic toxicity [125]. Neoadjuvant 
chemotherapy has not been shown to improve survival rates [57,63] and few 
data exist on adjuvant chemotherapy after radiation therapy. The use of 
concurrent chemotherapy and radiation therapy has been shown to increase 
survival rates in patients with oral cancers and other head and neck cancers 
[43, 148]. Unfortunately, most series have combined all head and neck sites, 
and it is difficult to interpret data for the oral cavity alone when sites such as the 
larynx, oropharynx and nasopharynx (which are very sensitive to 
chemoradiation therapy) are included. However, patients who have more 
extensive cancers are often treated with concurrent chemotherapy and 
radiation therapy. Studies have shown that chemotherapy given at the same 
time as radiation therapy is more effective than if it is given before or after a 




Radiotherapy (RT) involves the delivery of a precise radiation dose to the 
location of a malignant tumor or specific areas within the tumor to destroy the 
cancer cells. The careful treatment planning allows the surrounding normal 
tissues to be spared. It can be the only treatment in some early stage oral 
cancers and can be used as adjunct to chemotherapy or surgery to destroy 
small areas of cancer that could not be removed by the surgery. Elective 
irradiation of the N0 neck can also be performed in early stage oral cancer. 
Radiotherapy in the form of external beam therapy (EBT) or intensity 
modulated radiation therapy (IMRT) has been used to treat oral cancers and 
other head and neck cancers [20]. Brachytherapy can also be the mode of 
treatment [157]. The control rates of 86% for T1 and 75% for T2 oral cavity 
carcinoma by radiotherapy have been reported [88]. However, treatment with 
implants radiation has been associated with significant complications. About 
17% of the T1 lesions and almost 50% of the T2 lesions had soft-tissue 
necrosis when treated with iridium (Ir192) implants [25]. Wang has reported that 
the intraoral cone electron beam boost technique provides a superior cure rate 
compared to interstitial implant for T1 and T2 oral cancers [161]. When external 
beam radiation is the chosen treatment modality for oral carcinoma with N0 
neck, National Comprehensive Cancer Network (NCCN) has recommended a 
total dose of 70Gy to primary tumor and ≤ 50Gy to the neck at risk of occult 
metastasis. Both chemotherapy and radiotherapy may be associated with 
complications and this may be more marked in instances of poor pre-treatment 
evaluation and preparation [2,5,9,19]. 
 
The role of surgery as a single or combined therapy in the primary oral cancers 
treatment has been well documented. Although the outcome of radiotherapy 
and surgical treatment of oral carcinoma with clinical N0 neck is similar [107], 
some surgeons prefer surgery because it has the advantages of short term 
duration of treatment, low cost and proper staging of the tumor [6]. The surgical 
excision of the tumor may be performed with either laser or cold knife. 
However, issues have been raised concerning laser versus conventional 
excision of these lesions with cold knife or scalpel. The methodology is purely a 
technical choice, since the survival rate of about 80% for oral carcinoma with 
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clinically N0 neck does not change according to technique. Laser provides no 
distinct oncologic advantages over a standard surgical scalpel. However, it is 
very important for cure to have at least 1cm free tumor excision margin during 
surgery [143]. Metastasis of oral squamous cell carcinoma into the lymph 
nodes of the neck is common and reduces survival of the patient. It may 
therefore be necessary to include neck dissection in the complete surgical 
treatment of some of these patients. In instances of large oral cavity defect 
following tumor excision and not permitting direct primary closure, 
reconstruction with pedicle (such as pectoralis major, latissimus dorsi) or free 
micro vascular (such as radial forearm, latissimus dorsi, periscapular and 
antero-lateral thigh) myocutaneous flaps can be used [98,131,143].  
 
Biological therapy or immunotherapy is a type of therapy which utilizes the 
biological response modifiers (BRM) to boost the body immune system and 
enable it to directly or indirectly fight cancer cells. Although not specific for oral 
cavity cancers, it has been shown to reduce or control the side effects being 
experienced from other treatments like chemotherapy and radiotherapy. In 
future, this therapy may become relevant in the management of oral cancers 
with N0 neck. These biological response modifiers occur naturally in the body 
but they can also be produced in the laboratory [72,78]. These agents include 
interferons, interleukins, colony-stimulating factors, monoclonal antibodies, 
vaccines, gene therapy and nonspecific immune-modulating agents. Their 
exact mechanism of action is not fully known but they are thought to boost the 
power of the immune system to destroy or kill cancer cells such as T cells, NK 
cells and macrophages, make cancer cells more recognizable by the immune 
system, stop the process which changes normal cells to cancer cells, enhance 
the body system to repair or replace damaged normal cells and also keep the 
cancer cells from spreading to other parts of the body [72,78,89].  
 
Although elective neck dissection has been shown to reduce disease specific 
death rate and nodal recurrences in this study, it is not without morbidity and 
complications. It is therefore imperative that surgeons should pay close 
attention to their techniques so as to minimize the morbidities. The 
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complications that can arise from neck dissection include haemorrhage, air 
embolism, pneumothorax, chyle leak, facial edema, cervical fistula, limitation of 
shoulder movement (Frozen shoulder), paresthesia, and chronic neck and 
shoulder pain and carotid blow out [49,60,69,139]. 
 
The policy which advocates on the prevention of oral cavity cancer should be 
encouraged, promoted and supported. This is because prevention is usually 
better than cure, reducing economic loss, morbidity and death from the 
disease. Although the exact cause of oral carcinoma is unknown, it is expected 
that if exposure to the risk factors can be avoided, there may be a significant 
reduction in the incidence of oral cancer. Alcohol, cigarette, tobacco, areca or 
betel nuts are known risk factors for oral cancers. Social habits which 
discourage exposure to these risk factors may reduce the occurrence of oral 
cancer. Unfortunately, oral cancers have been reported in patients without 
exposure to these risk factors and others [62]. Plummer-Vinson syndrome has 
been associated with an increased risk of cancer of the oral cavity [6]. Larsson 
et al found out that an increased number of patients with this syndrome in part 
of Sweden accounted for the high rates of cancer of the oral cavity in females, 
and as the high rates of this syndrome have fallen in Sweden, so too has the 
incidence of oral cancer. In regions where hook worm infestation is rampant, 
the use of antihelminthics may also be protective against oral cancer as hook 
worm can cause chronic iron deficiency anaemia. Few reports exist on diet 
which may protect against oral cancers [90,93]. This includes eating of diet rich 
in fresh fruits and vegetables [91,94]. Epidemiologic evidence has suggested 
that vitamins A, C and carotenoids (present in fruits and vegetables) may be 
protective against epithelial cancers [91,94]. A decreased risk of oral cancer 
associated with vitamin A and C intake has been reported [6]. Also, 
consumption of trace elements and antioxidant vitamins has also been reported 
to be protective against development of oral cancers [94].  
 
After the primary treatment of oral cancer patients, they must be followed up in 
other to detect any recurrence early. National Comprehensive Cancer Network 
(NCCN) has recommended that during follow-up, the patients must be asked if 
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they have noticed any new developments or complaints and physical 
examinations of the patients must be performed every 1 – 3 months in the 1st 
year; every 2 – 4 months in the 2nd year, every 4 – 6 months in the 3rd to 5th 
year and every 6 – 12 months after 5 years of primary treatment. Chest 
imaging as clinically indicated must be performed or every 6 months. Also, 
thyroid function test especially to evaluate thyroid stimulating hormone (TSH) 
must be performed at least once in a year if the neck is irradiated. Speech, 
hearing and swallowing must be evaluated and rehabilitation carried out as 
indicated. Patients must be counselled on cessation from social habits like 
smoking of cigarette, chewing of tobacco, betel or areca nut and drinking of 


























There is no greater controversy on the management of oral cancers than the 
optimal treatment for clinical N0 necks. Researchers have however 
demonstrated that these clinical N0 neck have shown evidence of occult 
metastases in about 30% or higher, depending on the size, site of primary 
tumor and the histological diagnostic methods. The greatest challenge that is 
being faced by the head and neck oncologists and surgeons is the correct 
identification of the subset of these patients with cervical nodal micro 
metastases that will require elective neck treatment. Clinical palpation of the 
neck is grossly inadequate. Although the available radiological investigative 
tools have shown some improvement in the detection of neck metastasis but 
the sensitivity rates have been reported to be in the range of about 70 – 80%.  
Despite the increase in knowledge and advancement in cancer management, 
there is still no method to determine correctly the real micro metastatic disease 
free neck. Although squamous cell carcinoma of head and neck regions is a 
locally aggressive disease with a great tendency for loco-regional and distant 
metastasis, researchers have shown that not all the head and neck tumors 
metastasize, especially at the early stage. Treating the neck which is actually 
node negative means incurring unnecessary costs, prolong hospital stay and 
causing avoidable morbidity. However, when the neck is not included in the 
management plan for the primary tumor in a clinically N0 neck but with 
unidentified micro metastases, the implication of this is poor treatment outcome 
with increased morbidity and mortality rate.  
 
The reality is that some patients with a clinical N0 neck indeed have no cancer 
cells in the cervical lymphatics and their neck must not be over treated. In 
employing proper oncologic therapy for the neck, one must balance the desire 
to preserve the present function of the neck with the wish to prevent future 
morbidity or loss of neck function. This requires that all persons involved in the 
multimodality treatment of oral carcinomas; surgeons, radiation oncologists, 
and medical oncologists must have a unified therapeutic modality that may 
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achieve the desired goal, while minimizing morbidity. Although there are many 
available retrospective studies on oral cancers patients with clinical N0 necks 
and modalities of therapies but there is no consensus on the unique therapeutic 
approach. The benefits of elective neck dissection in patients with early oral 
cavity tumors have remained obscure. Few prospective studies are available 
but there is still inconclusive evidence on whether elective neck dissection is of 
any value over therapeutic neck dissection in oral cancers with N0 neck. A 
systematic review of prospective randomized controlled trials is needed to 
answer these questions owing to the inherently biased nature of the available 
studies. Only few of such randomized controlled trials are available in the 
literature and none of these studies have a study population above eighty 
patients. This study therefore systematically reviewed the existing published 
randomized controlled trials on the unresolved questions of elective versus 
therapeutic neck dissection in the clinically N0 neck of oral carcinoma and 
performed a meta-analysis of their data. The PRISMA (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses) guideline for randomized 
trials was followed. 
 
The objectives were to evaluate the effectiveness of elective neck dissection in 
the successful reduction of neck node recurrence in oral carcinomas with 
clinically N0 neck, to determine and compare the disease-specific death rate of 
elective neck dissection to the policy of observation in early oral squamous cell 
carcinoma with N0 neck and to compare the survival outcome of elective neck 
dissection to the policy of observation in oral squamous cell carcinomas. 
 
Out of the 613 studies identified during the comprehensive search, only 4 
randomized controlled trials met the criteria and were included in the meta-
analysis. The total number of patients from the studies was 283. All the studies 
had their patients randomized into two groups; END group and OBS group. 
There was no statistical difference between these two groups in terms of sex 
and age of patients, histologic type and staging. All the trials reported on the 
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patients’ pathologic distributions, neck recurrences and metastasis, survival 
and death outcome and follow-up.  
 
Despite the intention to include other factors as the primary outcome measures 
in this meta-analysis, the only clinically meaningful endpoint to measure the 
outcome benefit of elective neck dissection is the disease-specific death rate. 
The meta-analyses of these studies showed that elective neck dissection can 
effectively reduce the risk of death from the disease (disease-specific death) 
thereby, increasing the chance of survival {Fixed effect model RR=0.57, 95% 
CI of 0.36 - 0.89, p=0.014} or {Random effects model RR=0.59, 95% CI of 0.37 
- 0.96, p=0.034}. It is possible that this observed pooled effect in the meta-
analysis between END and OBS might have been largely influenced by the 
older studies. Perhaps, if the studies are conducted now that there are better 
investigative tools to identify and better stage neck node metastasis, this 
observed difference may be absent. 
 
There was also a significant evidence of reduction in neck nodal recurrences 
when elective neck dissection was performed. A few retrospective studies have 
reported on the survival benefit of elective neck dissection in early stage oral 
carcinoma. Only the study by Kligerman et al from this systematic review 
showed statistical significant evidence of disease-free survival rates benefit of 
elective neck dissection over observation. However, this systematic review did 
not show any significant survival outcome benefit of elective neck dissection 
over the policy of observation.  
 
In conclusion, the benefits of statistical significant reduction in disease-specific 
death rates and neck node recurrences may justify the need for elective neck 




7 Zusammenfassung  
Die optimale Behandlung des klinischen N0 Halses bei Mundhöhlenkarzinomen 
wird in der Literatur kontrovers diskutiert. Je nach Größe und Lage des 
Primärtumors sowie der Histologie liegt die okkulte Metastasierungsrate bei 
Patienten mit klinischem N0-Hals bei circa 30%. Kopf-Hals-Onkologen und -
Chirurgen stehen daher vor der Herausforderung, die Untergruppe der 
Patienten mit zervikalen, nodalen Mikrometastasen zu identifizieren, die einer 
elektiven Neck dissection zugeführt werden sollten. Die alleinige Palpation ist 
zur Bestimmung des Lymphknotenstatus absolut unzureichend. Die 
Sensitivitätsraten der bildgebenden Verfahren liegen trotz Verbesserungen in 
den letzten Jahren jedoch weiterhin nur bei 70 - 80%. Trotz der Zunahme an 
Wissen und Fortschritt in der Krebstherapie gibt es noch keine Methode zur 
korrekten Bestimmung der tatsächlichen Metastasierungssituation im Bereich 
des Halses. Obwohl Plattenepithelkarzinome des Kopf-Hals-Bereiches eine 
große Neigung zur Bildung von locoregionären und distanten Metastasen 
haben, konnten verschiedene Studien zeigen, dass vor allem Tumore in frühen 
Stadien häufig nicht metastasieren.  Die Operation von Patienten ohne 
manifeste Lymphknotenmetastasen führt zu unnötigen Kosten, einer 
Verlängerung des Krankenhausaufenthalts und vermeidbaren Komorbiditäten. 
Wird der Hals jedoch nicht in das Therapiekonzept miteinbezogen obwohl nicht 
identifizierte Mikrometastasen vorliegen, kann dies zu einem unvorteilhaften 
Behandlungsergebnis mit erhöhter Morbidität und Mortalität führen.  
 
Die Realität ist, dass bei einigen Patienten mit klinischem N0-Hals keine 
Lymphknotenmetastasen bestehen und diese Patienten nicht überbehandelt 
werden dürfen. Die optimale onkologische Therapie der Halslymphknoten muss 
daher zum Ziel haben, die Funktion zu erhalten und die Morbidität nach 
Möglichkeit zu minimieren, was eine multidisziplinäre Behandlung erfordert. 
 
Obwohl viele retrospektive Studien zu oralen Karzinomen mit klinischen N0-
Hals und deren Therapiemodalitäten vorliegen, gibt es keinen Konsens über 
die optimale Therapie und den etwaigen Nutzen einer elektiven Neck 
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dissection bei Patienten mit Mundhöhlenkarzinomen und N0-Hals. Es gibt in 
der Literatur nur wenige prospektive Studien zu diesem Thema und es gibt 
bisher keine Evidenz, ob eine elektive Neck dissection einer therapeutischen 
Neck dissection bei Patienten mit Mundhöhlenkarzinomen und N0-Hals 
überlegen ist. Eine systematische Analyse der vorliegenden prospektiven, 
randomisierten, kontrollierten Studien ist daher erforderlich, um diese Frage zu 
beantworten. Insgesamt gibt es nur wenige randomisierte, kontrollierte Studien 
und keine dieser Studien hat eine Patientenpopulation über 80 Patienten 
untersucht.  
 
Die vorliegende Analyse untersuchte systematisch publizierte randomisierte, 
kontrollierte Studien hinsichtlich ungelöster Fragen zur elektiven Neck 
dissection versus therapeutischen Neck dissection bei Patienten mit oralen 
Karzinomen und klinischem N0-Hals und erstellte eine Metaanalyse ihrer 
Daten. Die Studie folgte den PRISMA-Leitlinien (Preferred Reporting Items for 
Systematic reviews and Meta-Analyses).  
 
Das Ziel dieser Arbeit war, die Wirksamkeit der elektiven Neck dissection 
hinsichtlich der  Verringerung von Lymphknotenrezidiven bei Patienten mit 
oralen Karzinomen mit klinischem N0-Hals zu evaluieren und die 
krankheitsspezifische Mortalität sowie das Überleben von Patienten nach 
elektiver Neck dissection gegenüber Patienten, die keine Neck dissection 
erhielten, zu bestimmen und zu vergleichen. 
 
Aus 613 Studien, die während der umfassenden Suche identifiziert wurden, 
erfüllten nur 4 randomisierte, kontrollierte Studien die Einschlusskriterien und 
wurden in die Meta-Analyse eingeschlossen. Die Gesamtzahl der Patienten 
aus den Studien betrug 283. In allen Studien waren die Patienten in zwei 
Gruppen randomisiert: Elektive Neck dissection (END)-Gruppe und 
Observation (OBS)-Gruppe. Es gab keinen statistischen Unterschied zwischen 
diesen beiden Gruppen in Bezug auf Geschlecht und Alter der Patienten, 
histologischen Typ und Staging. Alle Studien untersuchten histologische 
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Entität, Rezidive im Bereich des Halses, Metastasen, Überleben und Follow-
Up.   
 
Trotz der Absicht, andere Faktoren als primäre Zielparameter in dieser Meta-
Analyse zu erfassen, ist der einzige klinisch bedeutungsvolle Endpunkt, um 
den Nutzen der elektiven Neck dissection zu messen, die krankheitsspezifische 
Mortalität. Die Meta-Analyse dieser Studien zeigte, dass die elektive Neck 
dissection die krankheitsspezifische Mortalität signifikant reduzieren kann und 
damit das Überleben verbessert {Fixed Effects-Modell RR = 0,57, 95% CI von 
0,36 bis 0,89 , p = 0,014} oder {Random Effects-Modell RR = 0,59, 95% CI von 
0,37 bis 0,96, p = 0,034}. Es ist jedoch möglich, dass dieser beobachtete 
Unterschied zwischen OBS- und END-Gruppe durch das Alter der Studien 
beeinflusst wurde und nicht zu beobachten wäre, wenn die Studien heute mit 
den neuesten Untersuchungsmethoden durchgeführt worden wären.  
Zusätzlich konnte gezeigt werden, dass die Durchführung einer elektiven Neck 
dissection das Risiko eines Lymphknotenrezidivs verringert. Eine verbesserte 
Überlebensrate nach elektiver Neck dissection bei Patienten mit frühen Stadien 
oraler Karzinome wurde ebenfalls in einigen retrospektiven Studien berichtet. 
Nur die Studie von Kligerman et al. [79] aus dieser systematischen 
Übersichtsarbeit zeigte einen statistisch signifikanten Nutzen der elektiven 
Neck dissection gegenüber engmaschiger Kontrolle hinsichtlich des 
krankheitsfreien Überlebens. Die systematische Übersichtsarbeit zeigte jedoch 
keinen signifikanten Vorteil der elektiven Neck dissection gegenüber wait-and-
see hinsichtlich des Überlebens. Zusammenfassend kann festgehalten werden, 
dass die statistisch signifikante Verringerung der krankheitsspezifischen 
Mortalität und Lymphknotenrezidivrate die Notwendigkeit einer elektiven Neck 
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